Search

Your search keyword '"Darunavir blood"' showing total 31 results

Search Constraints

Start Over You searched for: Descriptor "Darunavir blood" Remove constraint Descriptor: "Darunavir blood"
31 results on '"Darunavir blood"'

Search Results

1. Plasma, intracellular and lymph node antiretroviral concentrations and HIV DNA change during primary HIV infection: Results from the INACTION P25 study.

2. Brief Report: Pharmacokinetics of Bictegravir and Tenofovir in Combination With Darunavir/Cobicistat in Treatment-Experienced Persons With HIV.

Catalog

Books, media, physical & digital resources

3. Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model.

4. Higher plasma drug levels in elderly people living with HIV treated with darunavir.

5. Safety of hydroxychloroquine and darunavir or lopinavir in COVID-19 infection.

6. Low plasmatic concentration of intensified antiretroviral therapy in a pregnant woman: a case report.

7. Different effects of glucocorticoids on darunavir plasma concentrations.

8. Pharmacokinetic modelling of darunavir/ritonavir dose reduction (800/100 to 400/100 mg once daily) in a darunavir/ritonavir-containing regimen in virologically suppressed HIV-infected patients: ANRS 165 DARULIGHT sub-study.

9. Darunavir concentration in PBMCs may be a better indicator of drug exposure in HIV patients.

10. Drug-Drug Interactions Between PA-824 and Darunavir Based on Pharmacokinetics in Rats by LC-MS-MS.

11. HPLC Estimation, Ex vivo Everted Sac Permeability and In Vivo Pharmacokinetic Studies of Darunavir.

12. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.

13. Pharmacokinetics and pharmacodynamics of the nucleoside sparing dual regimen containing rilpivirine plus darunavir/ritonavir in treatment-naïve HIV-1-infected individuals.

14. Physiologically Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Coadministered With Ritonavir.

15. Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting.

16. Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.

17. The effect of veno-venous ECMO on the pharmacokinetics of Ritonavir, Darunavir, Tenofovir and Lamivudine.

18. Plasma and saliva concentrations of abacavir, tenofovir, darunavir, and raltegravir in HIV-1-infected patients
.

19. Once-daily atazanavir/cobicistat and darunavir/cobicistat exposure over 72 h post-dose in plasma, urine and saliva: contribution to drug pharmacokinetic knowledge.

20. Therapeutic drug monitoring of boosted PIs in HIV-positive patients: undetectable plasma concentrations and risk of virological failure.

21. Dolutegravir plasma concentrations according to companion antiretroviral drug: unwanted drug interaction or desirable boosting effect?

22. Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LC-MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a potential drug-drug interaction.

23. Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy.

24. Dried blood spot analysis of (+) and (-) darunavir enantiomers on immobilized amylose tris-(3, 5-dimethylphenylcarbamate) LC and its application to pharmacokinetics.

25. Darunavir and ritonavir total and unbound plasmatic concentrations in HIV-HCV-coinfected patients with hepatic cirrhosis compared to those in HIV-monoinfected patients.

26. Determination of abacavir, tenofovir, darunavir, and raltegravir in human plasma and saliva using liquid chromatography coupled with tandem mass spectrometry.

27. Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients.

28. Development and validation of a rapid ultra high performance liquid chromatography with tandem mass spectrometry method for the simultaneous determination of darunavir, ritonavir, and tenofovir in human plasma: Application to human pharmacokinetics.

29. Solid self-nanoemulsifying drug delivery system (S-SNEDDS) of darunavir for improved dissolution and oral bioavailability: In vitro and in vivo evaluation.

30. Antiretroviral blood levels in HIV/HCV-coinfected patients with cirrhosis after liver transplant: a report of three cases.

31. Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food.